Human epidermal growth factor receptor 2 (HER2) in gastric cancer: A new therapeutic target

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  De Vita, F ^a   Giuliani, F ^b   Silvestris, N ^b   Catalano, G ^a   Ciardiello, F ^a   Orditura, M ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Advanced gastric cancer; Gastroesophagal junction; HER2; Lapatinib; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

ABDOMINAL CRAMP; ADD ON THERAPY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SINGLE DRUG DOSE; STOMACH CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; HUMANS; QUINAZOLINES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 78649724338     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70014-1     Document Type: Article

References (42)

1. Terry M, Gaudet MM, Gammon MD The epidemiology of gastric cancer. Semin Radiat Oncol 2002, 12:111-127.
2. Sakamoto J, Morita S, Kodera Y, Rahman M, Nakao A Adjuvant chemothrapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemother Pharmacol 2004, 54(Suppl 1):S25-S31.
3. Blot WJ, McLaughlin JK The changing epidemiology of esophageal cancer. Semin Oncol 1999, 26:2-8.
4. Yang SH, Zhang YC, Yang KH, et al. An evidence-based medicine review of lymphadenectomy extent for gastric cancer. Am J Surg 2009, 197:246-251.
5. Sasako M, Sano T, Yamamoto S, et al. Japan Clinical Oncology Group. D2 Lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008, 359:453-462.
6. Schwarz RE, Smith DD Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 2007, 14:317-328.
7. De Vita F, Giuliani F, Galizia G, et al. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007, 18(Suppl 6):120-123.
8. Orditura M, Martinelli E, Galizia G, et al. Chemoradiotherapy as adjuvant chemotherapy of gastric cancer. Ann Oncol 2007, 18(Suppl 6):133-135.
9. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72:37-41.
10. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) pls supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71:587-591.
11. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8:163-168.
12. Ciardiello F, Tortora G EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
13. Tai W, Mahato R, Cheng K The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010 Apr 10, [Epub ahead of print].
14. Kaptain S, Lan LK, Chen B Her2/neu and breast cancer. Diagn Mol Pathol 2001, 10:139-152.
15. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986, 77(5):1047-1052.
16. Kang Y, Bang Y, Lordick F, et al. Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity (2008). ASCO Gastrointestinal Cancers Symposium 75 (Abs 11).
17. Cooperative Study Group of HER2 in China Multicenter study on HER-2/new gene amplification and protein expression in patients with gastric cancer. Chin J Dig 2006, 26:657-660.
18. Zhang XL, Yang YS, Xu DP, et al. Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer. World J Surg 2009, 33(10):2112-2118.
19. Tateishi M, Toda T, Minamisono Y, et al. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992, 49(4):209-212.
20. Sasano H, Date F, Imatani A, Asaki S, Nagura H Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993, 24:584-589.
21. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991, 51(3):1034-1038.
22. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein ingastric cancer. Its correlation with long-term survival of patients. Cancer 1993, 72(11):3179-3184.
23. Mizutani T, Onda M, Tokunaga A, et al. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993, 72:2083-2088.
24. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor associated protease systems. J Clin Oncol 2000, 18:2201-2209.
25. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:273-278.
26. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010, 32:57-65.
27. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131(1):18-43.
28. Nakhleh RE, Grimm EE, Idowu MO, Souers RJ, Fitzgibbons PL Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med 2010, 134(5):728-734.
29. Cuadros M, Villegas R Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 2009, 17(1):1-7.
30. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in firstline human epidermal growth factor receptor 2-positive advanced gastric cancer. J Clin Oncol (Meeting Abstracts) 2009, 27(15S):LBA4509.
31. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805.
32. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S Suppressionof tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005, 27:681-685.
33. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59:795-805.
34. Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008, 32:89-95.
35. Rech J, Arnold D, Folprecht G, et al. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. Ann Oncol 2006, 17(Suppl 9):314. (Abst 1096).
36. Cortés-Funes H, Rivera F, Alés I, et al. Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification. J Clin Oncol 2007, 15:18S. (Abst 4613).
37. Nicholas G, Cripps C, Au H-P, et al. Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2. Ann Oncol 2006, 17(Suppl 9):316. (Abst 1105).
38. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001, 1:85-94.
39. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
40. Kim JW, Kim HP, Im SA, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008, 272:296-306.
41. Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a Dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-Amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010, 1:1509-1519.
42. Satoh T, Bang Y, Wang J, et al. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol 2010, 28:15s. (Abst 4057).